Contact

Diagnosis of diseases" is in full investment mode


,
Integral service around a transaction
BY : Diego GutiérrezApril Wed, 2013

This sector of activity is immersed in an active movement of both corporate consolidation operations such as the one carried out by Progenika y Griffols as well as by several start-ups that are trying to carve out a niche for themselves in the complicated world of healthcare.

Corporate operations: Grifols acquires Progenika

The Catalan plasma derivatives multinational Grifols has bought 60% of the capital of the Basque biotech firm Progenika Biopharma 37 million in March 2013.
Grifols is the world's third largest producer of plasma-derived biological drugs, and is a pioneering group in the research and development of therapeutic alternatives.
Progenika specialises in the development of technology for personalised medicine, and focuses its activity on the design and production of genomic and proteomic tests for in vitro diagnosis, disease prognosis, response prediction and drug therapy monitoring.
In 2012, Grifols increased its profit fivefold, from 50.3 million euros in 2011 to 256.7 million euros at the end of last year.
The year-on-year profit growth of 410.2 % is explained by the acquisition of its US competitor Talecris, which it closed in June 2011, and the company's strong performance abroad, especially in the US and Canada.

Startups in action: Sword Diagnostic and Chronix

On the other hand, new initiatives are emerging, seeking new rounds of funding, which foresee the further development of new diagnostic systems. Some of these cases are:
- Sword Diagnostics

Espada Diagnostics high-throughput screening technology significantly improves the overall performance of biomedical assays and tests.

Chronix 

Chronix Biomedical, Inc. is a molecular diagnostics company, developing primarily blood tests for cancer, including companion diagnostics and tests for the detection of minimal residual disease.

More active funds: significant presence of VCs linked to pharmaceutical companies
In the first few months of 2013 we have seen VC funds related to multinational pharmaceutical companies enter the diagnostics sector. An example of this has been the Roche Fund's entry in March in Maculogix.

Diego Gutiérrez Zarza
ABRA INVEST
Web: www.abra-invest.com
Blog: http://abrainvest.wordpress.com/ 

The M&A Professionals

Meet our services

MEET
OUR
METODOLOGY

Do you want to be up to date?

SUSCRIBE OUR NEWSLETTER

Our diferentiation

Market Research Technology
Our team of market analysis specialists is continuously analyzing the investments of the most active markets in the industry in order to unceasingly contribute ideas of the current market situation and identify the most relevant trends for senior management. We integrate the most relevant sources of information which allows us to discover the most interesting companies for venture capital and similarly helps us to identify the investors with the highest probability of involvement in an M&A process to ensure the success of our sell-side operations.

The reports and deductions of our advisors provide a broad view of the sector, both geographically and from the complementary or adjacent markets perspective.
Technology Data Analytics
for M&A
Advanced data anlytics is a weapon". Intelfin is an artificial intelligence tool we use for investing and creating value in SMEs through competitive analytics and the enterprise environment.

IntelFin consists of a cognitive system, which, through the application of advanced analytical technologies, facilitates the automation of investment and financing decisions in the field of non-listed companies and especially SMEs in high-growth sectors.

The information related to these companies is characterized by their lack of transparency and heterogeneity; thus, it is necessary to develop an advanced analysis which is as much predictive as prescriptive and is developed in a natural language custom, suitable to obtain greater clarity and knowledge of the investment scope.

The IntelFin system focuses especially on analyzing the variables that define and influence the competitive environment of a sector and the positioning of a company, analyzing their influence on future value creation. Therefore, IntelFin supports strategic decision-making to senior management by resolving questions such as:

¿What are my competitors' priorities, strategies and expansion plans? Who's my competition? Which competitor is most likely to grow at a higher rate?
Which areas of activity/business models will receive the most investment? Which sectors are most attractive to investors?
Which companies are going to experience the most growth in the near future? Which companies are most likely to receive investment or be acquired?
Training Methodology
We have developed training programs in an innovative set-up which guarantees our teams the acquisition of technical competences both in the field of corporate finance and in the field of psychology, that is much needed when it comes to negotiation processes.

We have a culture of continuous improvement of our processes, closely related to the use of information systems that allow the enhancement of internal communication between our teams, as well as external communication with our customers. Hence, we extend best practices identified internally in an efficient and rapid manner among our members.

Are you one of those who prefer to be well informed when making decisions?

M&A NEWS
INDUSTRIAL REPORTS
closearrow-circle-o-downchevron-downcrossmenu